ZLAB News & Events

Zai Lab Limited announced new data from a preclinical study of ZL-1503, demonstrating that the company's internally developed IL-13/IL-31Ralpha bispecific antibody may lead to sustained suppression of intense pruritus and inflammation caused by atopic diseases. The findings, featured in a poster presentation at the IMMUNOLOGY2026 conference in Boston, MA, reinforce the potential of ZL-1503 to be a first-in-class treatment option for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases. "The breadth of activity across pruritus and atopic disease models in this study, including sustained suppression of symptoms from a single dose over 112 days, reinforces our belief that dual targeting of IL-13 and IL-31 pathways represents a compelling therapeutic approach," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "These data support our conviction that ZL-1503 has the potential to make a meaningful difference for patients and collectively support its clinical advancement."

Zai Lab announced clinical data indicating zocilurtatug pelitecan, a DLL3-targeting antibody-drug conjugate, provides rapid and robust intracranial responses in patients with previously treated extensive stage small cell lung cancer and brain metastases as measured by independent assessment using modified Response Assessment in Neuro-Oncology for Brain Metastases criteria, as well as promising data in patients with other neuroendocrine carcinomas. These findings, as well as preclinical data evaluating ZL-6201 and ZL-1222, will be presented at the American Association for Cancer Research Annual Meeting 2026 in San Diego. "The zoci data that we will present at AACR, alongside our ZL-6201 and ZL-1222 preclinical data, highlight the breadth, diversity and potential of our global oncology pipeline," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "The rapid progression of zoci into pivotal development, with three registration-enabling studies planned by the end of this year, is a prime example of our strategy to deliver our first global oncology launch. This accelerated progress is made possible by our unique integrated U.S.-China infrastructure, which allows us to evolve drug discovery into life-changing medicines with a focus on speed and quality."

Zai Lab (ZLAB) announced a global clinical trial collaboration with Amgen (AMGN) to evaluate Zai Lab's investigational delta-like ligand 3-targeting antibody-drug conjugate, zocilurtatug pelitecan, in combination with Amgen's Imdelltra, a DLL3-targeting Bispecific T-cell Engager, BiTE, therapy in patients with extensive-stage small cell lung cancer, ES-SCLC. As part of this collaboration agreement, Amgen will sponsor a global Phase 1b study to evaluate the safety and efficacy of zoci in combination with Imdelltra in patients with ES-SCLC. Zai Lab will retain full ownership of zoci and will supply Amgen with the study drug.